Actranex Film-Coated Tablet Special Precautions

In case of hematuria of renal origin (especially in hemophilia), there is a risk of mechanical anuria due to formation of a ureteral clot. Regular eye examinations (such as visual acuity, slit lamp, intraocular pressure, visual fields) and liver function tests should be performed in the long-term therapy of patients with hereditary angioneurotic edema.
Tranexamic acid should not be used by patients who have irregular menstrual bleeding until the source of the irregular bleeding has been determined. If Tranexamic acid does not adequately reduce monthly bleeding, an alternative treatment is recommended. Patients with thrombophilia who have had a past thromboembolic event and a family history of thromboembolic disease should use Tranexamic acid only if there is a substantial medical implication and under close medical supervision. Patients with renal impairment have elevated blood levels. As a result, a dose reduction is advised. Tranexamic acid should not be used in cases of enhanced fibrinolysis caused by disseminated intravascular coagulation. Treatment should be withdrawn from patients with visual disturbances.
Clinical experience with Tranexamic acid in menorrhagic children under 15 years of age is not available.
Potentially fatal: Because Tranexamic acid is antifibrinolytic, the risk of venous thromboembolism, as well as arterial thromboses such as stroke and myocardial infarction may increase further when combined hormonal contraceptives are administered with Tranexamic acid tablets. This is of particular concern in women who are obese or smoke cigarettes, especially smokers over 35 years of age.